



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1483.0370003/JMC/THNAPPLICATION NO.
10/644,783APPLICANT
Nancy C. LANFILING DATE
August 21, 2003GROUP
1614

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|-----|-----------------|------------|------------------|-------|-----------|-------------|
| B | AA1 | 4,024,175 | 05/17/1977 | Satzinger et al. | | | 12/31/1975 |
| | AB1 | 4,087,544 | 05/02/1978 | Satzinger et al. | | | 04/28/1977 |
| | AC1 | 4,602,017 | 07/22/1986 | Sawyer et al. | | | 02/27/1984 |
| | AD1 | 4,894,476 | 01/16/1990 | Butler et al. | | | 05/02/1988 |
| | AE1 | 5,025,035 | 06/18/1991 | Wallace | | | 10/12/1990 |
| | AF1 | 5,179,109 | 01/12/1993 | Kamenka et al. | | | 06/21/1990 |
| | AG1 | 5,236,957 | 08/17/1993 | Dostert et al. | | | 01/25/1991 |
| | AH1 | 5,256,669 | 10/26/1993 | Askanazi et al. | | | 08/07/1992 |
| | AI1 | 5,330,515 | 07/19/1994 | Rutecki et al. | | | 06/17/1992 |
| | AJ1 | 5,446,066 | 08/29/1995 | Varasi et al. | | | 03/22/1994 |
| | AK1 | 5,449,692 | 09/12/1995 | Varasi et al. | | | 03/22/1994 |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|-----|-----------------|------------|---------|-------|-----------|-------------|
| B | AL1 | WO 96/40628 | 12/19/1996 | WIPO | | | Yes No |
| | AM1 | WO 97/05102 | 02/13/1997 | WIPO | | | Yes No |
| | AN1 | WO 98/07447 | 02/26/1998 | WIPO | | | Yes No |
| | AO1 | WO 98/08842 | 03/05/1998 | WIPO | | | Yes No |
| | AP1 | WO 98/19674 A2 | 05/14/1998 | WIPO | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|---|----|---|---|
| B | AR | 1 | Backonja, M., et al., "Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus," JAMA 280:1831-1836, The American Medical Association (December 1998) |
| | AS | 1 | Bennett, G.J., "Neuropathic Pain: An Overview," in Molecular Neurobiology of Pain 9:109-113, Borshook, D., ed., IASP Press, Seattle (1997) |
| | AT | 1 | Bensimon, G., et al., "A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis," New England J. Med. 330:585-591, The Massachusetts Medical Society (1994) |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1483.0370003/JMC/THNAPPLICATION NO.
10/644,783APPLICANT
Nancy C. LANFILING DATE
August 21, 2003GROUP
1614

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|-----|-----------------|------------|-----------------------|-------|-----------|-------------|
| 4 | AA2 | 5,660,861 | 08/26/1997 | Jao et al. | | | 05/12/1995 |
| | AB2 | 5,712,277 | 01/27/1998 | Nakamura-Craig et al. | | | 07/15/1996 |
| | AC2 | 5,741,818 | 04/21/1998 | Dimmock | | | 06/07/1995 |
| | AD2 | 5,891,849 | 04/06/1999 | Amstutz et al. | | | 11/07/1997 |
| | AE2 | 5,905,069 | 05/18/1999 | Borsook et al. | | | 01/26/1998 |
| | AF2 | 5,942,510 | 08/24/1999 | Floyd et al. | | | 06/20/1996 |
| | AG2 | 6,113,915 | 09/05/2000 | Aoki et al. | | | 10/12/1999 |
| | AH2 | 6,180,624 B1 | 01/30/2001 | Hill | | | 02/25/1999 |
| | AI2 | 6,187,338 B1 | 02/13/2001 | Caruso et al. | | | 02/22/1999 |
| | AJ2 | 6,207,685 B1 | 03/27/2001 | Lallement et al. | | | 01/11/1999 |
| 5 | AK2 | 6,242,488 B1 | 06/05/2001 | Bueno et al. | | | 05/09/2000 |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|-----|-----------------|------------|---------|-------|-----------|-------------|
| 4 | AL2 | FR 2 756 738 | 06/12/1998 | France | | | X Yes No |
| | AM2 | WO 98/28255 | 07/02/1998 | WIPO | | | Yes No |
| | AN2 | WO 98/19674 A3 | 07/16/1998 | WIPO | | | Yes No |
| | AO2 | WO 98/43964 | 10/08/1998 | WIPO | | | Yes No |
| 3 | AP2 | WO 98/47869 | 10/29/1998 | WIPO | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|---|----|---|--|
| 4 | AR | 2 | Beydoun, A., "Postherpetic Neuralgia: Role of Gabapentin and Other Treatment Modalities," <i>Epilepsia</i> 40(Suppl. 6):S51-S56, Lippincott Williams & Wilkins (October 1999) |
| | AS | 2 | Blinder, B.J., et al., "Advances in Mood Stabilizing Medications," <i>West. J. Med.</i> 169:39-40, BMJ Publishing (1998) |
| 4 | AT | 2 | Boyce, S., et al., "Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn," <i>Neuropharmacology</i> 38:611-623, Pergamon and Elsevier Science Ltd. (May 1999) |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

::ODMA\MHODMA\SKGF_DC1;197764;1



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1483.0370003/JMC/THNAPPLICATION NO.
10/644,783APPLICANT
Nancy C. LANFILING DATE
August 21, 2003GROUP
1614U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|-----|-----------------|------------|------------------|-------|-----------|-------------|
| 4 | AA3 | 6,281,211 B1 | 08/28/2001 | Cai et al. | | | 09/21/2000 |
| | AB3 | 6,290,986 | 09/18/2001 | Murdock et al. | | | 06/29/1998 |
| 3 | AC3 | 6,326,374 B1 | 12/04/2001 | Magnus et al. | | | 06/18/1999 |
| | AD3 | 6,326,385 B1 | 12/04/2001 | Wickenden et al. | | | 08/04/2000 |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|-----|------------------|------------|---------|-------|-----------|-------------|
| 6 | AL3 | WO 99/12537 | 03/18/1999 | WIPO | | | Yes No |
| | AM3 | WO 99/26614 | 06/03/1999 | WIPO | | | Yes No |
| | AN3 | DE 198 02 327 A1 | 07/29/1999 | Germany | | | Yes X No |
| 2 | AO3 | WO 99/37296 | 07/29/1999 | WIPO | | | Yes No |
| | AP3 | WO 99/39712 | 08/12/1999 | WIPO | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|----|----|---|---|
| 8 | AR | 3 | Brown, C.M., et al., "Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia," <i>British J. Pharmacol.</i> 115:1425-1432, Stockton Press (1995) |
| | AS | 3 | Bryans, J.S., and Wustrow, D.J., "3-Substituted GABA Analogs with Central Nervous System Activity: A Review," <i>Med. Res. Rev.</i> 19:149-177, John Wiley & Sons, Inc. (March 1999) |
| 61 | AT | 3 | Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Clinical Stroke Trials Than NMDA Antagonists?," <i>Supplement I, Stroke</i> 24:I148-I152, American Heart Association (1993) |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

::ODMA\MHODMA\SKGF_DC1;197764;1



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1483.0370003/JMC/THNAPPLICATION NO.
10/644,783APPLICANT
Nancy C. LANFILING DATE
August 21, 2003GROUP
1614

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|-----|-----------------|------------|---------|-------|-----------|-------------|
| | AL4 | WO 99/44610 | 09/10/1999 | WIPO | | | Yes No |
| | AM4 | WO 99/61408 | 12/02/1999 | WIPO | | | X Yes No |
| | AN4 | WO 00/02562 | 01/20/2000 | WIPO | | | Yes No |
| | AO4 | WO 00/02592 | 01/20/2000 | WIPO | | | Yes No |
| | AP4 | WO 00/57877 | 10/05/2000 | WIPO | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|---|---|
| | AR | 4 | Canavero, S., et al., "The riddle of trigeminal neuralgia," Pain 60:229-231, Elsevier Science B.V. (1995) |
| | AS | 4 | Carrazana, E.J., and Schachter, S.C., "Alternative uses of lamotrigine and gabapentin in the treatment of trigeminal neuralgia," Neurology 50:1192, The American Academy of Neurology (April 1998) |
| | AT | 4 | Catterall, W.A., "Common modes of drug action on Na ⁺ channels: local anesthetics, antiarrhythmics and anticonvulsants," Trends Pharmacol. Sci. 8:57-65, Elsevier Science Publishers B.V. (1987) |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1483.0370003/JMC/THNAPPLICATION NO.
10/644,783APPLICANT
Nancy C. LANFILING DATE
August 21, 2003GROUP
1614

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|-----|-----------------|------------|---------|-------|-----------|-------------|
| | AL5 | EP 1 083 164 | 03/14/2001 | Europe | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|---|----|---|--|
| 3 | AR | 5 | Catterall, W.A., "Neurotoxins That Act on Voltage-sensitive Sodium Channels in Excitable Membranes," Ann. Rev. Pharmacol. Toxicol. 20:15-43, Annual Reviews Inc. (1980) |
| | AS | 5 | Catterall, W.A., "Structure and Function of Voltage-Sensitive Ion Channels," Science 242:50-61, The American Association for the Advancement of the Science (1988) |
| 9 | AT | 5 | Chapman, V., et al., "Effects of systemic carbamazepine and gabapentin on spinal neuronal responses in spinal nerve ligated rats," Pain 75:261-272, Elsevier Science B.V. (April 1998) |

EXAMINER

DATE CONSIDERED
12/8/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1483.0370003/JMC/THNAPPLICATION NO.
10/644,783APPLICANT
Nancy C. LANFILING DATE
August 21, 2003GROUP
1614

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|----|-----------------|------|---------|-------|-----------|-------------|
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|---|--|
| | AR | 6 | Creveling, C.R., et al., "Batrachotoxin-Induced Depolarization and [³ H]Batrachotoxinin-A 20 α -Benzoate Binding in a Vesicular Preparation from Guinea Pig Cerebral Cortex," <i>Mol. Pharmacol.</i> 23:350-358, The American Society for Pharmacology and Experimental Therapeutics (1983) |
| | AS | 6 | Czuczwar, S.J., and Przesmycki, K., "Felbamate, Gabapentin and Topiramate as Adjuvant Antiepileptic Drugs in Experimental Models of Epilepsy," <i>Polish J. Pharmacol.</i> 53:65-68, Polish Academy of Sciences (2001) |
| | AT | 6 | De Sarro, G., et al., "Gabapentin Potentiates the Antiseizure Activity of Certain Anticonvulsants in DBA/2 Mice," <i>Eur. J. Pharmacol.</i> 349:179-185, Elsevier Science (1998) |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1483.0370003/JMC/THNAPPLICATION NO.
10/644,783APPLICANT
Nancy C. LANFILING DATE
August 21, 2003GROUP
1614

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|----|-----------------|------|---------|-------|-----------|-------------|
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


| | | | |
|---|----|---|---|
| Q | AR | 2 | Denicoff, K.D., et al., "Efficacy of Carbamazepine Compared With Other Agents: A Clinical Practice Survey," <i>J. Clin. Psychiatry</i> 55:70-76, Physicians Postgraduate Press, Inc. (1994) |
| | AS | 2 | Dichter, M.A., et al., "Drug Therapy: New Antiepileptic Drugs," <i>New Engl. J. Med.</i> 334:1583-1590, Massachusetts Medical Society (1996) |
| Q | AT | 2 | Field, M.J., et al., "Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat," <i>Pain</i> 80:391-398, Elsevier Science B.V. (March 1999) |

EXAMINER

DATE CONSIDERED

12/8/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



| | | |
|--|--|-------------------------------|
| FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u> | ATTY. DOCKET NO. 1483.0370003/JMC/THN | APPLICATION NO. 10/644,783 |
| | APPLICANT Nancy C. LAN | |
| | FILING DATE August 21, 2003 | GROUP 1614 |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----|-----------------|------|------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |


| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|----|-----------------|------|---------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|---|---|
| | AR | 8 | Goldberg, I., and Green, B., "Focus on Gabapentin," Focus 8:1-6, Priory Lodge Education Ltd. (1997) from http://www.priory.com/focus8.htm |
| | AS | 8 | Graham, S.H., et al., "A Dose-Response Study of Neuroprotection Using the AMPA Antagonist NBQX in Rat Focal Cerebral Ischemia," J. Pharmacol. Exp. Therap. 276:1-4, Williams & Wilkins (1996) |
| | AT | 8 | Graham, S.H., et al., "Neuroprotective Effects of a Use-Dependent Blocker of Voltage-Dependent Sodium Channels, BW619C89, in Rat Middle Cerebral Artery Occlusion," J. Pharmacol. Exp. Therap. 269:854-859, Williams & Wilkins (1994) |

| | |
|--------------|----------------------------|
| EXAMINER | DATE CONSIDERED 12/8/03 |
|--------------|----------------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1483.0370003/JMC/THNAPPLICATION NO.
10/644,783APPLICANT
Nancy C. LANFILING DATE
August 21, 2003GROUP
1614

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----|-----------------|------|------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|----|-----------------|------|---------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|---|--|
| | AR | 2 | Gurney, et al., "Benefit of Vitamin E, Riluzole, and Gabapentin in a Transgenic Model of Familial Amyotrophic Lateral Sclerosis," <i>Ann. Neurol.</i> 39:147-157, The American Neurological Association (1996) |
| | AS | 2 | Hamill, O.P., et al., "Improved Patch-Clamp Techniques for High-Resolution Current Recording from Cells and Cell-Free Membrane Patches," <i>Pfluegers Arch</i> 391:85-100, Springer International (1981) |
| | AT | 2 | Hoekstra, M.S., et al., "Chemical Development of CI-1008, an Enantiomerically Pure Anticonvulsant," <i>Org. Process Res. Dev.</i> 1:26-38, American Chemical Society and Royal Society of Chemistry (1997) |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1483.0370003/JMC/THNAPPLICATION NO.
10/644,783APPLICANT
Nancy C. LANFILING DATE
August 21, 2003GROUP
1614




U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|----|-----------------|------|---------|-------|-----------|-------------|
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|---|----|-----------|--|
|  | AR | <u>10</u> | Hunskaar, S., et al., "Formalin test in mice, a useful technique for evaluating mild analgesics," <i>J. Neurosci. Methods</i> 14:69-76, Elsevier Science Publishers B.V. (1985) |
|  | AS | <u>10</u> | Iwasaki, Y., et al., "CNQX prevents spinal motor neuron death following sciatic nerve transection in newborn rats," <i>J. Neuro Sci.</i> 134:21-25, Elsevier Science B.V. (1995) |
|  | AT | <u>10</u> | Kim, S.H., et al., "An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat," <i>Pain</i> 50:355-363, Elsevier Science Publishers B.V. (1992) |

EXAMINER



DATE CONSIDERED



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



| | | |
|--|--|-------------------------------|
| FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u> | ATTY. DOCKET NO. 1483.0370003/JMC/THN | APPLICATION NO. 10/644,783 |
| | APPLICANT Nancy C. LAN | |
| | FILING DATE August 21, 2003 | GROUP 1614 |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----|-----------------|------|------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|----|-----------------|------|---------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|-----------|--|
| | AR | <u>11</u> | Kingery, W.S., "A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes," <i>Pain</i> 73:123-139, Elsevier Science B.V. (1997) |
| | AS | <u>11</u> | Kudoh, A., et al., "Effect of Carbamazepine on Pain Scores of Unipolar Depressed Patients with Chronic Pain: A Trial of Off-On-Off-On Design," <i>Clin. J. Pain</i> 14:61-65, Lippincott-Raven Publishers (1998) |
| | AT | <u>11</u> | Low, P.A., and Dotson, R.M., "Symptomatic Treatment of Painful Neuropathy," <i>JAMA</i> 280:1863-1864, The American Medical Association (December 1998) |

| | |
|--------------|---------------------|
| EXAMINER | DATE CONSIDERED |
|--------------|---------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1483.0370003/JMC/THNAPPLICATION NO.
10/644,783APPLICANT
Nancy C. LANFILING DATE
August 21, 2003GROUP
1614

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|----|-----------------|------|---------|-------|-----------|-------------|
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|-----------|---|
| | AR | <u>12</u> | Lunardi, G., et al., "Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia," <i>Neurology</i> 48:1714-1717, Lippincott-Raven Publishers (1997) |
| | AS | <u>12</u> | Magnus, L., "Nonepileptic Uses of Gabapentin," <i>Epilepsia</i> 40(Suppl. 6):S66-S72, Lippincott Williams & Wilkins (October 1999) |
| | AT | <u>12</u> | Nicholson, B., "Gabapentin use in neuropathic pain syndromes," <i>Dolor</i> 14:243-250, Publicaciones Permanyer (1999) |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.





| | | |
|--|--|-------------------------------|
| FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u> | ATTY. DOCKET NO. 1483.0370003/JMC/THN | APPLICATION NO. 10/644,783 |
| | APPLICANT Nancy C. LAN | |
| | FILING DATE August 21, 2003 | GROUP 1614 |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----|-----------------|------|------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |


| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|----|-----------------|------|---------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|---|----|-----------|--|
|  | AR | <u>13</u> | Ohizumi, Y., et al., "Specific Inhibitors of [³ H] Saxitoxin Binding to Skeletal Muscle Sodium Channels by Geographutoxin II, a Polypeptide Channel Blocker," J. Biol. Chem. 261:6149-6152, The American Society of Biological Chemists, Inc. (1986) |
| | AS | <u>13</u> | Rosenberg, J.M., et al., "The Effect of Gabapentin on Neuropathic Pain," Clin. J. Pain 13:251-255, Lippincott-Raven Publishers (1997) |
|  | AT | <u>13</u> | Rosner, H., et al., "Gabapentin Adjunctive Therapy in Neuropathic Pain States," Clin. J. Pain 12:56-58, Lippincott-Raven Publishers (1996) |

| | |
|---|--|
| EXAMINER  | DATE CONSIDERED  |
|---|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1483.0370003/JMC/THNAPPLICATION NO.
10/644,783APPLICANT
Nancy C. LANFILING DATE
August 21, 2003GROUP
1614




U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|----|-----------------|------|---------|-------|-----------|-------------|
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|---|----|-----------|---|
|  | AR | <u>14</u> | Rowbotham, M., et al., "Gabapentin for the Treatment of Postherpetic Neuralgia," JAMA 280:1837-1842, The American Medical Association (December 1998) |
|  | AS | <u>14</u> | Sheardown, M.J., et al., "AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h," Eur. J. Pharmacol. 236:347-353, Elsevier Science Publishers B.V. (1993) |
|  | AT | <u>14</u> | Sist, T.C., et al., "Experience With Gabapentin for Neuropathic Pain in the Head and Neck: Report of Ten Cases," Reg. Anesth. 22:473-478, The American Society of Regional Anesthesia (1997) |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1483.0370003/JMC/THNAPPLICATION NO.
10/644,783APPLICANT
Nancy C. LANFILING DATE
August 21, 2003GROUP
1614



U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|----|-----------------|------|---------|-------|-----------|-------------|
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|---|----|-----------|---|
|  | AR | <u>15</u> | Solaro, C., et al., "A patient with multiple sclerosis and Down's syndrome with a rare paroxysmal symptom at onset," Eur. J. Neurol. 6:505-507, Lippincott Williams & Wilkins. (July 1999) |
| | AS | <u>15</u> | Stys, P.K., et al., "Ionic Mechanisms of Anoxic Injury in Mammalian CNS White Matter: Role of Na ⁺ Channels and Na ⁺ -Ca ²⁺ Exchanger," J. Neurosci. 12:430-439, Society for Neuroscience (1992) |
|  | AT | <u>15</u> | Taylor, C.P., et al., "Na ⁺ channels as targets for neuroprotective drugs," Trends Pharmacol. Sci. 16:309-316, Elsevier Science Ltd. (1995) |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1483.0370003/JMC/THNAPPLICATION NO.
10/644,783APPLICANT
Nancy C. LANFILING DATE
August 21, 2003GROUP
1614

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|----|-----------------|------|---------|-------|-----------|-------------|
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|----|--|
| | AR | 16 | Verdoorn, T.A., et al., "Functional Properties of Recombinant Rat GABA _A Receptors Depend upon Subunit Composition," <i>Neuron</i> 4:919-928, Cell Press (1990) |
| | AS | 16 | Victor, M., et al., "Chapter 352: Diseases of the Cranial Nerves," in <i>Harrison's Principles of Internal Medicine</i> 11:2035-2040, Braunwald, et al., eds., McGraw-Hill Inc. (1987) |
| | AT | 16 | Wamil, A.W., and McLean, M.J., "Limitation by gabapentin of high frequency action potential firing by mouse central neurons in cell culture," <i>Epilepsy Res.</i> 17:1-11, Elsevier Science B.V. (1994) |

EXAMINER

DATE CONSIDERED
2/18/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

::ODMA\MHODMA\SKGF_DCI;197764;1



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1483.0370003/JMC/THNAPPLICATION NO.
10/644,783APPLICANT
Nancy C. LANFILING DATE
August 21, 2003GROUP
1614

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|----|-----------------|------|---------|-------|-----------|-------------|
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|-----------|--|
| | AR | <u>17</u> | Wrathall, J.R., et al., "Amelioration of Functional Deficits from Spinal Cord Trauma with Systemically Administered NBQX, an Antagonist of Non-N-methyl-D-aspartate receptors," <i>Exp. Neurology</i> 137:119-126, Academic Press, Inc. (1996) |
| | AS | <u>17</u> | Yoon, M.H., and Yaksh, T.L., "Evaluation of Interaction between Gabapentin and Ibuprofen on the Formalin Test in Rats," <i>Anesthesiology</i> 91:1006-1013, Lippincott Williams & Wilkins, Inc. (October 1999) |
| | AT | <u>17</u> | Dialog File 351, Accession No. 12613976, Derwent WPI English language abstract for DE 198 02 327 A1 (Document AN3) |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1483.0370003/JMC/THNAPPLICATION NO.
10/644,783APPLICANT
Nancy C. LANFILING DATE
August 21, 2003GROUP
1614

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|----|-----------------|------|---------|-------|-----------|-------------|
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|----|--|
| | AR | 18 | List of abstracts concerning SCRIP 1773:14 (1992) provided by client |
| | AS | 18 | List of abstracts concerning SCRIP 1870:8 (1993) provided by client |
| | AT | 18 | STN Database, Accession No. 1998:9096, "Warner-Lambert forecasts 35% earnings growth," SCRIP 2330:8 (1998) |

EXAMINER

DATE CONSIDERED
14/8/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



| | | |
|--|--|-------------------------------|
| FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u> | ATTY. DOCKET NO. 1483.0370003/JMC/THN | APPLICATION NO. 10/644,783 |
| | APPLICANT Nancy C. LAN | |
| | FILING DATE August 21, 2003 | GROUP 1614 |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----|-----------------|------|------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|----|-----------------|------|---------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

| OTHER (Including Author, Title, Date, Pertinent Pages, etc.) | | | |
|--|----|-----------|--|
| | AR | <u>19</u> | United States Application No. 60/126,553, Hogenkamp et al., filed March 26, 1999 |
| | AS | <u>19</u> | Attal, N., "Antiepileptic drugs in the treatment of neuropathic pain," <i>Exp. Rev. Neurotherapeutics</i> 1:199-206, Future Drugs Ltd. (2001) |
| | AT | <u>19</u> | Bennett, G.J., "Neuropathic Pain: New Insights, New Interventions," <i>Hospital Practice</i> 33:95-98, 101-104, 107-110, 113-114, The McGraw-Hill Companies, Inc. (1998) |

| | |
|--------------|---------------------|
| EXAMINER | DATE CONSIDERED |
|--------------|---------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1483.0370003/JMC/THNAPPLICATION NO.
10/644,783APPLICANT
Nancy C. LANFILING DATE
August 21, 2003GROUP
1614

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|----|-----------------|------|---------|-------|-----------|-------------|
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|---|----|----|---|
| 9 | AR | 20 | Borowicz, K.K., et al., "Effect of Gabapentin on the Anticonvulsant Activity of Antiepileptic Drugs against Electroconvulsions in Mice: An Isobolographic Analysis," <i>Epilepsia</i> 43:956-963, Blackwell Publishing, Inc. (2002) |
| | AS | | |
| | AT | | |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.